One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis
An Interview With Rgenix Co-Founders Masoud and Sohail Tavazoie
Executive Summary
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.
You may also be interested in...
Finance Watch: The Growing $100m-Plus VC Club
Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.
C-Suite Snippets: Targeting Metastasis In Cancer Therapy
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.